Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

Planned

The registry lists NCT07553390 as not yet recruiting, last updated 2026-08-19. Enrolment is 60 planned participants, an estimate. Interventions: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

Setting

Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07553390

Started

2026-10-01 (estimated)

Enrolled

Connected

cancers

Breast cancer (all types)

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: planned0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Cancers

Breast cancer (all types)

Targets

TROP2

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07553390

A source that has moved or gone is reported by the weekly link check. /audit/

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

Planned

Setting

Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07553390

Started

2026-10-01 (estimated)

Enrolled

Connected

cancers

Breast cancer (all types)

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: planned0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Cancers

Breast cancer (all types)

Targets

TROP2

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07553390

A source that has moved or gone is reported by the weekly link check. /audit/

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

Overview

Connected

cancers

targets

Sources

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

Overview

Connected

cancers

targets

Sources